Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
3.520
-0.260 (-6.88%)
At close: Jun 16, 2026, 4:00 PM EDT
3.491
-0.029 (-0.82%)
After-hours: Jun 16, 2026, 6:52 PM EDT
Zentalis Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
106
Market Cap
250.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 67.43M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 157.08M |
| Niagen Bioscience | 130.42M |
| Bicycle Therapeutics | 63.50M |
| Surrozen | 7.49M |
| Armata Pharmaceuticals | 5.20M |
| Cartesian Therapeutics | 1.78M |
| Inhibikase Therapeutics | 1.00 |
ZNTL News
- 1 day ago - Zentalis assumed with an Outperform at Oppenheimer - TheFly
- 13 days ago - Zentalis Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 15 days ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy - GlobeNewsWire
- 20 days ago - Zentalis Pharmaceuticals Proxy statement: Proxy filing - Filings
- 21 days ago - Zentalis Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 26 days ago - Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 - GlobeNewsWire
- 27 days ago - Zentalis Pharmaceuticals Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts